Trials / Terminated
TerminatedNCT00667420
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | panitumumab, epirubicin, oxaliplatin, xeloda | pilot study |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-06-01
- Completion
- 2014-06-01
- First posted
- 2008-04-28
- Last updated
- 2014-07-04
- Results posted
- 2014-07-04
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00667420. Inclusion in this directory is not an endorsement.